FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
9 letters match. Newest first.
-
DrugsUSV Private Limited
FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.
High risk -
DrugsJabil Inc.
FDA warned Jabil Inc. after an inspection found inadequate investigations of mold and sterility failures at its sterile injectable contract manufacturer.
High risk -
DrugsEugia Pharma Specialities Limited
FDA warned Eugia Pharma Specialities that flawed aseptic line design and poor aseptic practices at its Kolthur Village plant risk contaminating sterile injectables.
High risk -
DrugsFareva Amboise
FDA warned Fareva Amboise in France about sterile drug manufacturing failures, including aseptic practice and data integrity problems.
High risk -
DrugsWizcure Pharmaa Private Limited
FDA warned Wizcure Pharmaa about serious manufacturing and data-integrity failures in sterile OTC drugs.
High risk -
DrugsFagron BV
FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.
High risk -
DrugsCareFusion 213, LLC
FDA warns CareFusion 213 over inadequate investigations and contamination controls at its El Paso sterile drug plant.
High risk -
DrugsPar Health USA, LLC & Endo USA, Inc.
FDA cited Par Health USA/Endo USA’s Rochester plant for sterile injectable contamination-control, media fill, and visual inspection failures after an October 2025 inspection.
High risk -
DevicesMAST Biosurgery USA, Inc.
MAST Biosurgery USA never ran promised endotoxin tests on its SurgiWrap FROST surgical mesh and failed to report patient injuries, FDA says.
High risk